PET de doble fase con 18F-FDOPA como instrumento para la caracterización de tumores cerebrales

  1. M. González-Forero
  2. Elena Prieto Azcárate
  3. Inés Domínguez Prado
  4. Carmen Vigil Díaz
  5. Iván Peñuelas Sánchez
  6. Javier Arbizu Lostao
Revista española de medicina nuclear

ISSN: 0212-6982

Ano de publicación: 2011

Volume: 30

Número: 2

Páxinas: 88-93

Tipo: Artigo


Outras publicacións en: Revista española de medicina nuclear


18F-FDOPA is an amino acid analogue used to evaluate presynaptic dopaminergic activity, which has aroused great interest in neuro-oncology. We have evaluated five 18F-FDOPA PET studies of patients referred for study of parkinsonian syndrome. Two subjects had previously treated high-grade brain tumors, one nonspecific brain injury, and 2 subjects presented unexpected tumoral lesions. For all lesions SUVmax, time to SUVmax and tumor-to-normal grey matter SUVmax rate (T/N) were calculated, and 90minutes 18F-FDOPA kinetics were analyzed. Tumor lesions corresponded to three malignant neurocytomas, one meningioma, one pineocytoma and one intrasinusal hemangioma. Both malignant and benign tumors exhibited high uptake of 18F-FDOPA well above the normal cortex. However, the analysis of the curve uptake displayed characteristic patterns that facilitate the characterization of tumor lesions. A dual phase maximum uptake was observed, with an early 10minutes uptake in malignant lesions, and a late 60 to 90minutes uptake in benign or low grade lesions.